PureTech Health plc (FRA:0VQ)

Market Cap	369.50M -6.5%
Revenue (ttm)	5.44M +1,265.6%
Net Income	43.15M
EPS	0.17
Shares Out	n/a
PE Ratio	8.56
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	270
Open	1.510
Previous Close	1.550
Day's Range	1.510 - 1.510
52-Week Range	1.160 - 1.870
Beta	n/a
RSI	50.51
Earnings Date	Apr 29, 2026

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 56
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0VQ

Financial Performance

Financial numbers in USD